TBPH Stock Analysis: Theravance Biopharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 883m USD | 12M Return: 23.5% | KYG8807B1068 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.16M
Qual. Beats: 0
Rev. Trend: 93.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Theravance Biopharma (NASDAQ: TBPH) is a U.S.-based biopharmaceutical company incorporated in 2013 and headquartered in South San Francisco that develops and commercializes respiratory and neurology medicines. Its commercial product is YUPELRI, a once-daily nebulized long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Its lead pipeline asset, Ampreloxetine, is an investigational once-daily norepinephrine reuptake inhibitor currently in Phase 3 development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
The company commercializes YUPELRI through a strategic collaboration with Viatris, a common arrangement in the pharmaceutical industry where a larger partner handles manufacturing, distribution, and field sales while the originating company contributes development and royalty rights. As a small-cap healthcare stock (GICS Pharmaceuticals sub-industry), TBPHs value is closely tied to the progression of its late-stage clinical pipeline and the commercial trajectory of its partnered respiratory product.
- YUPELRI sales accelerate with Viatris partnership expansion
- Ampreloxetine Phase 3 results in MSA patients near-term catalyst
- Cash runway tightens amid elevated R&D spending
| Net Income: 53.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 7.90 > 1.0 |
| NWC/Revenue: 369.9% < 20% (prev 403.7%; Δ -33.73% < -1%) |
| CFO/TA 0.11 > 3% & CFO 51.8m > Net Income 53.8m |
| Net Debt (-249.2m) to EBITDA (68.5m): -3.64 < 3 |
| Current Ratio: 13.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.7m) vs 12m ago 1.86% < -2% |
| Gross Margin: 88.02% > 18% (prev 47.33%; Δ 40.69% > 0.5%) |
| Asset Turnover: 23.29% > 50% (prev 18.12%; Δ 5.17% > 0%) |
| Interest Coverage Ratio: 26.11 > 6 (EBIT TTM 64.3m / Interest Expense TTM 2.46m) |
| A: 0.82 (Total Current Assets 416.7m - Total Current Liabilities 30.8m) / Total Assets 469.8m |
| B: -1.85 (Retained Earnings -870.5m / Total Assets 469.8m) |
| C: 0.14 (EBIT TTM 64.3m / Avg Total Assets 447.9m) |
| D: 1.61 (Book Value of Equity 289.7m / Total Liabilities 180.1m) |
| Altman-Z'' = 2.00 = BBB |
| DSRI: 0.69 (Receivables 20.4m/21.9m, Revenue 104.3m/77.2m) |
| GMI: 0.54 (GM 47.33% / 88.02%) |
| AQI: 0.89 (AQ_t 0.06 / AQ_t-1 0.06) |
| SGI: 1.35 (Revenue 104.3m / 77.2m) |
| TATA: 0.00 (NI 53.8m - CFO 51.8m) / TA 469.8m) |
| Beneish M = -3.52 (Cap -4..+1) = AAA |
As of August 26, 2026, the stock is trading at USD 17.03 with a total of 332,379 shares traded. Over the past week, the price has changed by +0.47%, over one month by +1.01%, over three months by +3.78% and over the past year by +23.45%.
Current recommended Stop Loss: 16.80 (which is 1.4% or 2.9 ATR below the current price).
Theravance Biopharma has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold TBPH.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.7 | 3.8% |
P/E Trailing = 16.3558
P/E Forward = 5.596
P/S = 8.4664
P/B = 3.0394
P/EG = -0.05
Revenue TTM = 104.3m USD
EBIT TTM = 64.3m USD
EBITDA TTM = 68.5m USD
Long Term Debt = 27.8m USD (estimated: total debt 38.6m - short term 10.8m)
Short Term Debt = 10.8m USD (from shortTermDebt, last quarter)
Debt = 79.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 40.5m
Net Debt = -249.2m USD (calculated: Debt 79.1m - CCE 328.3m)
Enterprise Value = 633.9m USD (883.1m + Debt 79.1m - CCE 328.3m)
Interest Coverage Ratio = 26.11 (Ebit TTM 64.3m / Interest Expense TTM 2.46m)
EV/FCF = 8.20x (Enterprise Value 633.9m / FCF TTM 77.3m)
FCF Yield = 12.19% (FCF TTM 77.3m / Enterprise Value 633.9m)
FCF Margin = 74.10% (FCF TTM 77.3m / Revenue TTM 104.3m)
Net Margin = 51.58% (Net Income TTM 53.8m / Revenue TTM 104.3m)
Gross Margin = 88.02% ((Revenue TTM 104.3m - Cost of Revenue TTM 12.5m) / Revenue TTM)
Gross Margin QoQ = 93.04% (prev 91.88%)
Tobins Q-Ratio = 1.35 (Enterprise Value 633.9m / Total Assets 469.8m)
Interest Expense / Debt = 3.11% (Interest Expense 2.46m / Debt 79.1m)
Taxrate = 8.67% (5.11m / 58.9m)
NOPAT = 58.7m (EBIT 64.3m * (1 - 8.67%))
Current Ratio = 13.26 (Total Current Assets 416.7m / Total Current Liabilities 31.4m)
Debt / Equity = 0.27 (Debt 79.1m / totalStockholderEquity, last quarter 289.7m)
Debt / EBITDA = -3.64 (Net Debt -249.2m / EBITDA 68.5m)
Debt / FCF = -3.22 (Net Debt -249.2m / FCF TTM 77.3m)
Total Stockholder Equity = 277.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.01% (Net Income 53.8m / Total Assets 469.8m)
RoE = 19.40% (Net Income TTM 53.8m / Total Stockholder Equity 277.4m)
RoCE = 21.06% (EBIT 64.3m / Capital Employed (Equity 277.4m + L.T.Debt 27.8m))
RoIC = 13.20% (NOPAT 58.7m / Invested Capital 444.6m)
WACC = 6.96% (E(883.1m)/V(962.2m) * Re(7.33%) + D(79.1m)/V(962.2m) * Rd(3.11%) * (1-Tc(0.09)))
Discount Rate = 7.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.38 | Cagr: 3.06%
[DCF] Terminal Value 77.97% ; FCFF base≈61.0m ; Y1≈69.9m ; Y5≈102.8m
[DCF] Fair Price = 34.61 (EV 1.55b - Net Debt -249.2m = Equity 1.80b / Shares 51.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.18 | # QB: 0
Revenue Correlation: 93.65 | Revenue CAGR: 30.05% | SUE: -0.39 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.20 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.21 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+241.8% | GrowthRev=-15.6%
EPS next Year (2027-12-31): EPS=1.27 | Chg30d=+59.37% | Revisions=+0% | GrowthEPS=+507.1% | GrowthRev=+7.4%
[Analyst] Revisions Ratio: +0% (up=0, down=0)